Report
Novo agrees to pay up to $2.6 billion to license Hengrui Pharma’s experimental weekly weight-loss pill
STAT reports the agreement is for a pill from China’s Hengrui Pharma that remains experimental.
TLDR
STAT reports Novo has agreed to pay up to $2.6 billion to license an experimental weekly weight-loss pill from China’s Hengrui Pharma.
Combined views
1.6K
1 Source, first seen 4h ago
1 likes